

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)

28 August 2015

**PRIMA BIOMED WILL PRESENT AT THE 17TH ANNUAL RODMAN & RENSHAW
GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY, SEPTEMBER 8-10TH, 2015**

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced it will present at the 17th Annual Rodman & Renshaw Global Investment Conference at the St. Regis Hotel in New York City.

Marc Voigt, CEO of Prima BioMed, will provide a presentation on the Company on Wednesday September 9, 2015.

About Prima BioMed

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Prima’s original product, called CVac, is an *ex vivo* dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima’s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

About Rodman & Renshaw Conferences, LLC

The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

For further information please contact:

Prima BioMed Ltd:

Stuart Roberts

+61 (0) 447 247 909; stuart.roberts@primabiomed.com.au

Australia Investor/Media:

Mr Matthew Gregorowski, Citadel Communications

+61 (0) 422 534 755; mgregorowski@citadelpr.com.au